Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 74Colorectal Neoplasms 43Rectal Neoplasms 42Stomach Neoplasms 39Triple Negative Breast Neoplasms 30Neoplasm Metastasis 19Esophageal Neoplasms 16Colonic Neoplasms 16Neoplasms 13Pancreatic Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Nasopharyngeal Carcinoma 11Adenocarcinoma 11Biliary Tract Neoplasms 10Adenocarcinoma Of Esophagus 9Cholangiocarcinoma 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Brain Neoplasms 6Anus Neoplasms 6Recurrence 5Neuroendocrine Tumors 5Gastrointestinal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4HER2-positive Breast Cancer 4Colorectal Cancer Metastatic 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Pathologic Complete Response 3

Interventions

Specimen Handling 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Radiosurgery 2Liver Transplantation 2Gemcitabine 2Cisplatin 2Biopsy 2tislelizumab 1sacituzumab govitecan 1gemcitabine-oxaliplatin regimen 1fludarabine 1dehydroftorafur 1binimetinib 1Tegafur 1S 1 (combination) 1Pancreatic Hormones 1Leucovorin 1Hydroxychloroquine 1Cyclophosphamide 1Cholangiopancreatography, Endoscopic Retrograde 1Capecitabine 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Klatskin Tumor × Capecitabine × 1 year × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡